Limits...
Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors

View Article: PubMed Central - PubMed

ABSTRACT

Background: Met and HER-2 are proto-oncogenes encoding receptor tyrosine kinase c-Met and HER-2, respectively. Hepatocyte growth factor (HGF) is a ligand of c-Met. The frequency of c-Met, HGF, and HER-2 expressions in gastric cancer and their association with other clinicopathological factors have not been fully understood.

Patients and methods: Patients with stage 1–4 disease were analyzed. Expressions of c-Met, HGF, and HER-2 were examined using immunohistochemistry.

Results: A total of 143 patients, 97 males and 46 females, were included. C-Met scores were 3(+) in 31.5%, 2(+) in 27.3%, and 1(+) in 10.5% of the patients. There was no statistically significant difference in age, sex, tumor location, differentiation, Lauren classification, TNM staging, presence of distant metastasis, depth of tumor invasion (T), lymphovascular invasion, and survival between c-Met subgroups. Overall HGF positivity was 20.6%. HER-2 scores were 3(+) in 9.1%, 2(+) in 9.8%, and 1(+) in 16.1% of the patients. HER-2 overexpression was associated with better differentiation, intestinal subtype, and advanced stage. C-Met overexpressions were 84.6% in the HER-2-overexpression-positive group and 56.2% in the HER-2-overexpression-negative group. There were no statistically significant differences in survival between the high c-Met-expression-positive and -negative stage 3 and stage 4 patients and between the HGF-positive and -negative groups. The mean survival was 11.6±6.3 months in the HER-2-overexpression-positive stage 4 group and 11.9±6.8 months in the HER-2-overexpression-negative stage 4 group. There were no statistically significant differences in survival between the two groups.

Conclusion: c-Met was not associated with any prognostic factors in gastric cancer. HER-2 was associated with better differentiation, intestinal subtype, advanced stage, and c-Met overexpression.

No MeSH data available.


Survival curve of all patients.Note: The median overall survival was 21.2 months in 102 patients who were included in survival analysis.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5036569&req=5

f1-ott-9-5809: Survival curve of all patients.Note: The median overall survival was 21.2 months in 102 patients who were included in survival analysis.

Mentions: Paraffin tumor blocks of 150 gastric cancer patients were achieved but clinical information of seven cases were missing. Finally, 143 cases, 97 males and 46 females, were included. The mean age was 57.3±13.1 (range 28–90 years). C-Met scores were 3(+) in 31.5%, 2(+) in 27.3%, and 1(+) in 10.5% and negative in 30.8% of the patients. C-Met expression (2+ and 3+) rate was 58.7% (84/143). HER-2 scores were 3(+) in 9.1%, 2(+) in 9.8%, 1(+) in 16.1%, and negative in 65.0% of the patients. HGF was positive in 20.6% and negative in 79.4% of the patients (n=126; Table 2). The median overall survival was 21.2±3.8 months in 102 patients who were included in the survival analysis (Figure 1).


Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors
Survival curve of all patients.Note: The median overall survival was 21.2 months in 102 patients who were included in survival analysis.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5036569&req=5

f1-ott-9-5809: Survival curve of all patients.Note: The median overall survival was 21.2 months in 102 patients who were included in survival analysis.
Mentions: Paraffin tumor blocks of 150 gastric cancer patients were achieved but clinical information of seven cases were missing. Finally, 143 cases, 97 males and 46 females, were included. The mean age was 57.3±13.1 (range 28–90 years). C-Met scores were 3(+) in 31.5%, 2(+) in 27.3%, and 1(+) in 10.5% and negative in 30.8% of the patients. C-Met expression (2+ and 3+) rate was 58.7% (84/143). HER-2 scores were 3(+) in 9.1%, 2(+) in 9.8%, 1(+) in 16.1%, and negative in 65.0% of the patients. HGF was positive in 20.6% and negative in 79.4% of the patients (n=126; Table 2). The median overall survival was 21.2±3.8 months in 102 patients who were included in the survival analysis (Figure 1).

View Article: PubMed Central - PubMed

ABSTRACT

Background: Met and HER-2 are proto-oncogenes encoding receptor tyrosine kinase c-Met and HER-2, respectively. Hepatocyte growth factor (HGF) is a ligand of c-Met. The frequency of c-Met, HGF, and HER-2 expressions in gastric cancer and their association with other clinicopathological factors have not been fully understood.

Patients and methods: Patients with stage 1–4 disease were analyzed. Expressions of c-Met, HGF, and HER-2 were examined using immunohistochemistry.

Results: A total of 143 patients, 97 males and 46 females, were included. C-Met scores were 3(+) in 31.5%, 2(+) in 27.3%, and 1(+) in 10.5% of the patients. There was no statistically significant difference in age, sex, tumor location, differentiation, Lauren classification, TNM staging, presence of distant metastasis, depth of tumor invasion (T), lymphovascular invasion, and survival between c-Met subgroups. Overall HGF positivity was 20.6%. HER-2 scores were 3(+) in 9.1%, 2(+) in 9.8%, and 1(+) in 16.1% of the patients. HER-2 overexpression was associated with better differentiation, intestinal subtype, and advanced stage. C-Met overexpressions were 84.6% in the HER-2-overexpression-positive group and 56.2% in the HER-2-overexpression-negative group. There were no statistically significant differences in survival between the high c-Met-expression-positive and -negative stage 3 and stage 4 patients and between the HGF-positive and -negative groups. The mean survival was 11.6±6.3 months in the HER-2-overexpression-positive stage 4 group and 11.9±6.8 months in the HER-2-overexpression-negative stage 4 group. There were no statistically significant differences in survival between the two groups.

Conclusion: c-Met was not associated with any prognostic factors in gastric cancer. HER-2 was associated with better differentiation, intestinal subtype, advanced stage, and c-Met overexpression.

No MeSH data available.